Luigi Frati

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11027615/publications.pdf

Version: 2024-02-01

73 papers	3,602 citations	126907 33 h-index	133252 59 g-index
74 all docs	74 docs citations	74 times ranked	4757 citing authors

#	Article	IF	Citations
1	Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scandinavian Journal of Gastroenterology, 2016, 51, 1257-1262.	1.5	14
2	Implementing the Risk of Ovarian Malignancy Algorithm Adding Obesity as a Predictive Factor. Anticancer Research, 2016, 36, 6425-6430.	1.1	2
3	Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. International Journal of Cancer, 2015, 137, 1491-1497.	5.1	34
4	Triple-negative breast cancer: new perspectives for targeted therapies. OncoTargets and Therapy, 2015, 8, 177.	2.0	109
5	Hepatitis C virus present in the sera of infected patients interferes with the autophagic process of monocytes impairing their in-vitro differentiation into dendritic cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1348-1355.	4.1	21
6	Effect of Serenoa repens (PermixonÂ®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. Journal of Inflammation, 2013, 10, 11.	3.4	22
7	HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumor Biology, 2012, 33, 1291-1298.	1.8	22
8	Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumor Biology, 2012, 33, 1335-1339.	1.8	52
9	Liver CT evaluation using a software that automatically generates report according to RECIST 1.1 criteria.. Journal of Clinical Oncology, 2012, 30, e14096-e14096.	1.6	0
10	Early defect of transforming growth factor Î²1 formation in Huntingtonâ€™s disease. Journal of Cellular and Molecular Medicine, 2011, 15, 555-571.	3.6	64
11	Notch3 and Canonical NF-ÎºB Signaling Pathways Cooperatively Regulate Foxp3 Transcription. Journal of Immunology, 2011, 186, 6199-6206.	0.8	73
12	HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report. International Journal of Molecular Sciences, 2011, 12, 627-632.	4.1	9
13	HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biology, 2010, 31, 113-119.	1.8	159
14	Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumor Biology, 2010, 31, 411-415.	1.8	50
15	Notch3 and pTÎ±/pre-TCR sustain the in vivo function of naturally occurring regulatory T cells. International Immunology, 2009, 21, 727-743.	4.0	28
16	Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1113-1120.	6.4	52
17	Tenascin C: A defensive role in sentinel lymph nodes of melanoma patients?. Journal of Dermatological Science, 2009, 53, 239-241.	1.9	2
18	Distinct Brain Volume Changes Correlating with Clinical Stage, Disease Progression Rate, Mutation Size, and Age at Onset Prediction as Early Biomarkers of Brain Atrophy in Huntington's Disease. CNS Neuroscience and Therapeutics, 2009, 15, 1-11.	3.9	69

#	Article	IF	Citations
19	Molecular medicine: predicting and preventing Huntingtonâ€™s disease. Neurological Sciences, 2008, 29, 205-207.	1.9	5
20	Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD). Blood, 2008, 112, 5237-5237.	1.4	1
21	Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO Journal, 2007, 26, 1670-1680.	7.8	74
22	Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood, 2006, 107, 3313-3320.	1.4	37
23	Notch3 and pre-TCR interaction unveils distinct NF-Î°B pathways in T-cell development and leukemia. EMBO Journal, 2006, 25, 1000-1008.	7.8	130
24	Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. Journal of Nuclear Medicine, 2006, 47, 215-22.	5.0	201
25	PKCÎ¸ mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene, 2005, 24, 992-1000.	5.9	67
26	Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene, 2004, 23, 2640-2647.	5.9	101
27	New mutations and protein variants ofNBS1 are identified in cancer cell lines. Genes Chromosomes and Cancer, 2003, 36, 198-204.	2.8	15
28	Preâ€TCRâ€triggered ERK signallingâ€dependent downregulation of E2A activity in Notch3â€induced Tâ€cell lymphoma. EMBO Reports, 2003, 4, 1067-1071.	4.5	69
29	Notch, a unifying target in T-cell acute lymphoblastic leukemia?. Trends in Molecular Medicine, 2003, 9, 30-35.	6.7	37
30	Survivin, bcl-2, bax, and bcl-X Gene Expression in Sentinel Lymph Nodes From Melanoma Patients. Journal of Clinical Oncology, 2003, 21, 306-312.	1.6	90
31	Expression of Activated Notch3 in Transgenic Mice Enhances Generation of T Regulatory Cells and Protects against Experimental Autoimmune Diabetes. Journal of Immunology, 2003, 171, 4504-4511.	0.8	120
32	Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Reports, 2003, 4, 1067-1071.	4.5	24
33	Combined expression of pTÎ± and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3788-3793.	7.1	184
34	Human MRE11 is inactivated in mismatch repairâ€deficient cancers. EMBO Reports, 2002, 3, 248-254.	4.5	169
35	Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. Journal of Pathology, 2001, 195, 343-348.	4.5	69
36	The adaptor protein shc is involved in the negative regulation of NK cell-mediated cytotoxicity. European Journal of Immunology, 2001, 31, 2016-2025.	2.9	28

#	Article	IF	Citations
37	Augmentation of leukocyte infiltration in murine tumors expressing B-cell derived but not nasopharyngeal carcinoma derived EBV membrane protein LMP1. , 2000, 60, 417-424.		5
38	CD69-triggered ERK activation and functions are negatively regulated by CD94 / NKG2-A inhibitory receptor. European Journal of Immunology, 2000, 30, 644-651.	2.9	66
39	Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. European Journal of Neuroscience, 2000, 12, 1002-1012.	2.6	158
40	Identification of an Estrogen-Mediated Deoxyribonucleic Acid-Binding Independent Transactivation Pathway on the Epidermal Growth Factor Receptor Gene Promoter*. Endocrinology, 2000, 141, 2266-2274.	2.8	38
41	CD69-triggered ERK activation and functions are negatively regulated by CD94â€‰/â€‰NKG2-A inhibitory receptor. , 2000, 30, 644.		1
42	CD69-triggered ERK activation and functions are negatively regulated by CD94â€‰/â€‰NKG2-A inhibitory receptor. European Journal of Immunology, 2000, 30, 644-651.	2.9	4
43	Identification of an Estrogen-Mediated Deoxyribonucleic Acid-Binding Independent Transactivation Pathway on the Epidermal Growth Factor Receptor Gene Promoter. Endocrinology, 2000, 141, 2266-2274.	2.8	9
44	Concurrent Chemoimmunotherapy in Metastatic Clear Cell Sarcoma: A Case Report. Tumori, 1999, 85, 512-514.	1.1	19
45	Expression pattern of Notch1, 2 and 3 and Jagged1 and 2 in lymphoid and stromal thymus components: distinct ligandâ€“receptor interactions in intrathymic T cell development. International Immunology, 1999, 11, 1017-1025.	4.0	180
46	Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunology, Immunotherapy, 1999, 47, 272-277.	4.2	31
47	Tyrosine kinase-dependent ubiquitination of CD16 Î¶ subunit in human NK cells following receptor engagement. European Journal of Immunology, 1999, 29, 3179-3187.	2.9	21
48	Thrombospondin-1 Is a Mediator of the Neurotypic Differentiation Induced by EGF in Thymic Epithelial Cells. Experimental Cell Research, 1999, 248, 79-86.	2.6	15
49	Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype. Oncogene, 1998, 16, 2767-2772.	5.9	43
50	Two gamma-interferon-activation sites (GAS) on the promoter of the human intercellular adhesion molecule (ICAM-1) gene are required for induction of transcription by IFN-gamma. FEBS Journal, 1998, 258, 968-975.	0.2	35
51	Novel deletion at codon 1254 of the BRCA1 gene in an Italian breast cancer kindred. Human Mutation, 1998, 11, S237-S239.	2.5	4
52	CD16-mediated activation of phosphatidylinositol-3 kinase (Pl-3K) in human NK cells involves tyrosine phosphorylation of Cbl and its association with Grb2, Shc, pp36 and p85 Pl-3K subunit. European Journal of Immunology, 1998, 28, 1005-1015.	2.9	28
53	Origin and Gender Determination of Dried Blood on a Statue of the Virgin Mary. Journal of Forensic Sciences, 1998, 43, 431-434.	1.6	7
54	Cloning of a novel human RNA polymerase II subunit downregulated by doxorubicin: new potential mechanisms of drug related toxicity. FEBS Letters, 1996, 384, 48-52.	2.8	22

#	Article	IF	Citations
55	Involvement of an Arachidonic-Acid-Dependent Pathway in the Interferon-beta-Mediated Expression of C202 Gene in Ehrlich-Ascites-Tumor Cells. FEBS Journal, 1996, 235, 91-96.	0.2	3
56	Tyrosine kinase-dependent activation of human NK cell functions upon triggering through CD44 receptor. European Journal of Immunology, 1996, 26, 2807-2811.	2.9	27
57	bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. , 1996, 69, 100-104.		95
58	BAX Gene Expression in Melanoma Metastases. Journal of Investigative Dermatology, 1996, 106, 382.	0.7	3
59	High cell kinetics is associated with amplification of theint-2,bcl-1,myc anderbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers. International Journal of Cancer, 1995, 61, 1-6.	5.1	28
60	Microsatellite instability and pathological aspects of breast cancer. International Journal of Cancer, 1995, 64, 264-268.	5.1	50
61	Involvement of p21ras activation in T cell CD69 expression. European Journal of Immunology, 1994, 24, 616-620.	2.9	149
62	Transcriptional regulation of interleukin-2 gene expression by CD69-generated signals. European Journal of Immunology, 1993, 23, 2993-2997.	2.9	36
63	Continuousin vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. European Journal of Immunology, 1993, 23, 3104-3108.	2.9	77
64	Evidence for nuclear internalization of exogenous DNA into mammalian sperm cells. Molecular Reproduction and Development, 1993, 34, 133-139.	2.0	100
65	Differential expression of granzyme A and granzyme B proteases and their secretion by fresh rat natural killer cells (NK) and lymphokine-activated killer cells with NK phenotype (LAK-NK). European Journal of Immunology, 1992, 22, 1049-1053.	2.9	38
66	In Vivo modulation of the distribution of thymocyte subsets: Effects of estrogen on the expression of different T cell receptor VÎ² gene families in CD4â^', CD8â^' thymocytes. Cellular Immunology, 1991, 134, 414-426.	3.0	53
67	Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study. Cancer, 1991, 68, 56-61.	4.1	21
68	Inhibition of NK Cell Generation by Corynebacterium Parvum. Immunopharmacology and Immunotoxicology, 1991, 13, 513-529.	2.4	1
69	Augmentation of Mouse Natural Killer (NK) Activity by GM-1/P, A Processed form of Monosialoganglioside GM-1. Immunopharmacology and Immunotoxicology, 1990, 12, 545-563.	2.4	2
70	Enhancement of Lymphocyte Proliferation and Il-2 Receptor Expression by A Processed Form (Gm-1/P) of Monosialoganglioside GM-1. Immunopharmacology and Immunotoxicology, 1990, 12, 565-582.	2.4	2
71	Characterization of Corynebacterium Parvum-Induced Suppressor Cells of Mouse NK and ADCC Activity. Immunopharmacology and Immunotoxicology, 1990, 12, 363-387.	2.4	0
72	Granzyme A expression by normal rat natural killer (NK) cellsin vivo and by interleukin 2-activated NK cellsin vitro. European Journal of Immunology, 1989, 19, 575-578.	2.9	15

#	Article	IF	Citations
73	Modulation of natural killer (NK) cell activity during FLV-P virus infection of mice. International Journal of Cancer, 1983, 31, 81-90.	5.1	13